BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:Bispecifics and T-cell engagers are redefining the future of s olid tumor treatment. With the landmark approvals of tarlatamab and ivone scimab\, the spotlight is firmly on these modalities as powerful solution s for long-standing unmet needs. At the same time\, the field is rapidly evolving beyond first-generation designs\, with innovations in co-stimula tion\, conditional activation\, multispecific engineering\, and affinity tuning aimed at deepening response rates while mitigating dose-limiting t oxicities.\n\nInnovation is rife within Korea\, with companies such as AB L Bio\, Novelty Nobility\, ABION\, and IM Biologics capturing internation al attention and investment\, positioning Korea as a key player in the bi specific and TCE revolution.\n\nTo accelerate this momentum\, the inaugur al World Bispecific and T-Cell Engager Summit South Korea comes as the on ly event in Asia dedicated to bringing together biopharma professionals f ocused on the discovery and development of differentiated Bispecifics and T-cell engagers that could become first-in-class therapies. Featuring ke y international opinion leaders\, the agenda will deep dive into co-stimu lation techniques\, conditional activation\, affinity window engineering\ , and bispecific ADCs (bsADCs)\, spotlighting cutting-edge strategies to expand the therapeutic window\, overcome antigen escape\, reduce CRS\, an d improve clinical predictability.\n\nAs part of the World Targeted Thera peutics Summit South Korea\, organized by Hanson Wade\, this is your oppo rtunity to converge with peers working on antibody-drug conjugates (ADCs) \, targeted protein degradation\, and induced proximity\, which aim to tu rn South Korea into the next global hub for biopharma innovation in targe ted therapeutics. From discovery to manufacturing\, you'll get end-to-end coverage to equip your entire team with the insights needed to innovate and differentiate\, ultimately attract interest for global pharma partner ships.\n\nURLs:Website: \;https://go.evvnt.com/3521884-0?pid=185Ticke ts: \;https://go.evvnt.com/3521884-2?pid=185Brochure: \;https://g o.evvnt.com/3521884-3?pid=185\n\nPrices:Drug Developer Pricing - 3 Day Pa ss (Workshop Day + Conference): USD 2548.00\,Drug Developer Pricing - 2 D ay Pass (Conference Only): USD 1849.00\,Academic Pricing - 3 Day Pass (Wo rkshop Day + Conference): USD 2298.00\,Academic Pricing - 2 Day Pass (Con ference Only): USD 1649.00\,Service Provider Pricing - 3 Day Pass (Worksh op Day + Conference): USD 5198.00\,Service Provider Pricing - 2 Day Pass (Conference Only): USD 3899.00\n\nSpeakers: \;Aaron Sato\, Chief Stra tegy Officer\, Adimab\, JJ You\, Vice President\, Antibody Discovery\, AP Biosciences\, Saso Cemerski\, Executive Director\, Head of Immune Engage rs\, AstraZeneca\, Bin Zou\, Founder and Chief Executive Officer\, Axcyns is\, Longli Zhou\, Senior Researcher\, Beacon by Hanson Wade\, Mingjiu Ch en\, Founder\, Chairman and Chief Executive Officer\, Biosion\, Leticia C orrales\, Laboratory Head\, Boehringer Ingelheim\, Shumin Liu\, President \, Enduring Biotech\, Ertan Eryilmaz\, Vice President\, Biologics\, InduP ro\, Katsuaki Usami\, Principal Investigator\, Innovation Center\, Kyowa Kirin\, David DiLillo\, Executive Director\, Immune-Oncology\, Regeneron\ , Nitin Damle\, Executive Vice President and Chief Innovation Officer\, S un Pharma\, Jing Li\, Chief Executive Officer\, VelaVigo\, Alexey Berezhn oy\, Director\, Immunology\, Zymeworks\, Sangmi Lee\, Clinical Developmen t Head\, ABL Bio\, Jinwon Jung\, Senior Director\, ABL Bio\, Chris Kim\, Chief Executive Officer\, CelleMEDY\, Manheum Na\, Head\, New Biological Drug Department\, Celltrion\, Nari Yun\, Chief Development Officer\, GI I nnovation\, Young Su Noh\, Director\, Head of Clinical Research and Devel opment\, Hanmi Pharm\, Jin-San Yoo\, President\, R and D\, PharmAbcine\, WonGyun Ahn\, Associate Director\, Qurient\, Shawn Seong\, Chief Executiv e Officer\, Shaperon\n\nCategory: \;Conferences | Science\, Health an d Medicine | Pharmaceuticals\n\nDate and Time: \;9th June 2026 at 8:0 0 am to 11th June 2026 at 4:30 pm\n\nVenue details: \;COEX Magok Le W est\, 143 Magokjungang-ro\, Gangseo-gu\, Seoul\, Korea (South)\n DTEND:20260611T163000 DTSTAMP:20260512T220031Z DTSTART:20260609T080000 LOCATION:COEX Magok Le West\, 143\, Magokjungang-ro\, Gangseo-gu\, Seoul\, SEQUENCE:0 SUMMARY:Bispecifics and T-cell engagers are redefining the future of solid tumor treatment. With the landmark approvals of tarlatamab and ivonescim ab\, the... UID:0afa0b25-ff3f-432f-9dbd-c5fc248a39d5 END:VEVENT END:VCALENDAR